Skip to main content
SpringerLink
Log in

Resistant Hypertension: Definition, Prevalence, and Therapeutic Approaches

  • Chapter
Pathophysiology and Pharmacotherapy of Cardiovascular Disease

  • 4307 Accesses

Abstract

Resistant hypertension (RH) is defined as blood pressure (BP) above goal despite adherence to at least three optimally dosed antihypertensive medications of different classes, one of which is a diuretic. Not all patients with BP that is difficult to control have RH. Evaluation of possible RH begins with assessment of adherence to medications. White-coat effect should be ruled out by out-of-office BP monitoring. Obesity, heavy alcohol intake, and interfering substances all contribute to RH. Lifestyle modifications including exercise and dietary sodium restriction are important to emphasize. RH may be due to secondary causes such as renal disease, obstructive sleep apnea, and/or aldosteronism. Adequate diuretic treatment is a key part of therapy. Chlorthalidone is more potent and longer-lasting than hydrochlorothiazide and may reduce cardiovascular events to a greater extent. For patients with a glomerular filtration rate <30 ml/min, a loop diuretic is usually needed. In addition to a diuretic, patients with RH should usually be on a dihydropyridine calcium channel blocker and either an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II AT1 receptor blocker (ARB). Spironolactone is an evidence-based fourth-line agent for treatment of RH. Other add-on medication options include a beta-blocker, a long-acting nondihydropyridine calcium channel blocker, or clonidine. When BP is not coming under control despite the prescription of four or five agents, referral to a hypertension specialist should be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Centers for Disease Control (CDC). Ambulatory care use and physician office visits. http://www.cdc.gov/nchs/fastats/physician-visits.htm. Accessed 21 Sept 2014.

  2. Go AS, Mozaffarian D, Roger VL, American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart and stroke statistics 2014 update. A report from the American Heart Association. Circulation. 2014;129:e28–292.

    Article  PubMed  Google Scholar 

  3. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.

    Article  PubMed  Google Scholar 

  4. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72.

    Article  CAS  PubMed  Google Scholar 

  5. Centers for Disease Control (CDC). Morbidity and Mortality Weekly Report (MMWR). Vital signs: prevalence, treatment, and control of hypertension—United States, 1999–2002 and 2005–2008. 2011;60(04):103–8.

    Google Scholar 

  6. Hyman DJ, Pavlik VN. Poor hypertension control: let’s stop blaming the patients. Cleve Clin J Med. 2002;69:793–9.

    Article  PubMed  Google Scholar 

  7. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19.

    Article  CAS  PubMed  Google Scholar 

  8. Calhoun DA, Booth JN, Oparil S, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014;63:451–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57:1076–80.

    Article  CAS  PubMed  Google Scholar 

  10. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898–902.

    Article  PubMed  Google Scholar 

  11. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA. 1993;269:2779–81.

    Article  CAS  PubMed  Google Scholar 

  12. Viera AJ, Jamieson B, Dealleaume L. Clinical inquiries. How effective are hypertension self-care interventions? J Fam Pract. 2007;56:229–31.

    PubMed  Google Scholar 

  13. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713–9.

    Article  PubMed  Google Scholar 

  14. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans. A statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697–716.

    Article  PubMed  Google Scholar 

  15. Reeves RA. The rational clinical examination. Does this patient have hypertension? How to measure blood pressure. JAMA. 1995;273:1211–8.

    Article  CAS  PubMed  Google Scholar 

  16. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens. 2001;14:1263–9.

    Article  CAS  PubMed  Google Scholar 

  17. Myers MG, Valdivieso M, Kiss A. Use of automated office blood pressure measurement to reduce the white coat response. J Hypertens. 2009;27:280–6.

    Article  CAS  PubMed  Google Scholar 

  18. Pickering TG, White WB. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens. 2008;2:119–24.

    Article  PubMed  Google Scholar 

  19. Verberk WJ, Kroon AA, Kessels AG, et al. The optimal scheme of self blood pressure measurement as determined from ambulatory blood pressure recordings. J Hypertens. 2006;24(8):1541–8.

    Article  CAS  PubMed  Google Scholar 

  20. Egan BM, Zhao Y, Axon N, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046–58. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–09.

    Google Scholar 

  21. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878–84.

    Article  CAS  PubMed  Google Scholar 

  22. Mann JF, Schmieder RE, McQueen M, ONTARGET Investigators, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.

    Article  CAS  PubMed  Google Scholar 

  23. Calhoun DA, Nishizaka MK, Zaman MA, Thakar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892–6.

    Article  CAS  PubMed  Google Scholar 

  24. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161–5.

    Article  CAS  PubMed  Google Scholar 

  25. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37:699–705.

    Article  CAS  PubMed  Google Scholar 

  26. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371:1921–62.

    Article  CAS  PubMed  Google Scholar 

  27. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266–81.

    Article  CAS  PubMed  Google Scholar 

  28. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19:2271–7.

    Article  CAS  PubMed  Google Scholar 

  29. Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation. 2003;107(1):68–73.

    Article  PubMed  Google Scholar 

  30. Eklöf H, Ahlström H, Magnusson A, et al. A prospective comparison of duplex ultrasonography, captopril renography, MRA, and CTA in assessing renal artery stenosis. Acta Radiol. 2006;47:764–74.

    Article  PubMed  Google Scholar 

  31. Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361:1953–62.

    Article  PubMed  Google Scholar 

  32. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium restriction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:444–6.

    Article  Google Scholar 

  33. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.

    Article  Google Scholar 

  34. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255–64.

    Google Scholar 

  35. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352–8.

    Article  CAS  PubMed  Google Scholar 

  36. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43(1):4–9.

    Article  CAS  PubMed  Google Scholar 

  37. Ernst ME, Neaton JD, Grimm RH, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the Multiple Risk Factor Intervention Trial. Hypertension. 2011;58:1001–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57:689–94.

    Article  CAS  PubMed  Google Scholar 

  39. Grogan JR, Kochar MS. Alcohol and hypertension. Arch Fam Med. 1994;3:150–4.

    Article  CAS  PubMed  Google Scholar 

  40. Viera AJ, Kshirsagar AV, Hinderliter AL. Lifestyle modification advice for lowering or controlling high blood pressure: who’s getting it? J Clin Hypertens (Greenwich). 2007;9:850–8.

    Article  Google Scholar 

  41. Diaz KM, Booth JN, Calhoun DA, et al. Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stoke Study. Hypertension. 2014;64:465–71. [epub ahead of print].

    Google Scholar 

  42. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3–10.

    Article  CAS  PubMed  Google Scholar 

  43. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839–45.

    Article  CAS  PubMed  Google Scholar 

  44. Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069–75.

    Article  CAS  PubMed  Google Scholar 

  45. Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005;46:481–7.

    Article  CAS  PubMed  Google Scholar 

  46. Saseen JJ, Carter BL, Brown TE, Elliott WJ, Black HR. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension. 1996;28(1):109–14.

    Article  CAS  PubMed  Google Scholar 

  47. Bakris G. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001;161:2661–7.

    Article  CAS  PubMed  Google Scholar 

  48. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens. 2010;23:1031–7.

    Article  CAS  PubMed  Google Scholar 

  49. Egan BM, Basile JN, Rehman SU, et al. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22:792–801.

    Article  CAS  PubMed  Google Scholar 

  50. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.

    Article  PubMed  Google Scholar 

  51. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–09.

    Google Scholar 

  52. Bhatt DL, Kandzari DE, O’Neill WW, SYMPLICITY HTN-3 Investigators, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401.

    Article  CAS  PubMed  Google Scholar 

  53. Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006;44:1213–8.

    Article  PubMed  Google Scholar 

  54. Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56:1254–8.

    Article  PubMed  Google Scholar 

  55. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension. Results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J Am Coll Cardiol. 2011;58:765–73.

    Article  PubMed  Google Scholar 

  56. Viera AJ. Resistant hypertension. J Am Board Fam Med. 2012;25(4):487–95.

    Article  PubMed  Google Scholar 

  57. Frank J. Managing hypertension using combination therapy. Am Fam Physician. 2008;77:1279–86.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Family Medicine, Hypertension Research Program, University of North Carolina at Chapel Hill School of Medicine, 590 Manning Drive, CB 7595, Chapel Hill, NC, 27599, USA

    Anthony J. Viera MD, MPH, FAHA

Authors
  1. Anthony J. Viera MD, MPH, FAHA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony J. Viera MD, MPH, FAHA .

Editor information

Editors and Affiliations

  1. Center for Drug Evaluation and Research Division of Cardiovascular and Renal Products, US Food and Drug Administration, Silver Spring, Maryland, USA

    Gowraganahalli Jagadeesh

  2. Pharmacology Unit, AIMST University, Bedong, Malaysia

    Pitchai Balakumar

  3. Center for Drug Evaluation and Research Division of Cardiovascular and Renal Products, US Food and Drug Administration, Silver Spring, Maryland, USA

    Khin Maung-U

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Viera, A.J. (2015). Resistant Hypertension: Definition, Prevalence, and Therapeutic Approaches. In: Jagadeesh, G., Balakumar, P., Maung-U, K. (eds) Pathophysiology and Pharmacotherapy of Cardiovascular Disease. Adis, Cham. https://doi.org/10.1007/978-3-319-15961-4_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-15961-4_42

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-15960-7

  • Online ISBN: 978-3-319-15961-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation